SAMe to prevent liver damage from oxaliplatin chemotherapy for colorectal cancer
Part of Cancer, Digestive system, Heart & circulation clinical trials.
This trial tests whether a dietary supplement called SAMe can protect the liver from damage caused by oxaliplatin, a chemotherapy drug for colorectal cancer that has spread to the liver. If you are planning to have liver surgery after chemotherapy, this study might help reduce liver side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have stage IV colorectal cancer that has spread to the liver and is removable with surgery
- You will receive oxaliplatin-based chemotherapy and then have liver surgery
- You are in reasonably good health (able to do daily activities)
- You do not have severe nerve damage from previous treatment
- You are not currently taking certain antidepressants or antipsychotics, and you are willing to avoid them during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This trial tests if a supplement called alpha-lipoic acid (ALA) can protect against painful mouth sores caused by chemotherapy (FOLFOX-6) in people with colorectal cancer. If you are starting FOLFOX-6 for the first time for colorectal cancer, this study may help reduce treatment side effects.
This trial tests whether adjusting the dose of chemotherapy drugs (5-FU or capecitabine plus oxaliplatin) based on a liver enzyme test can improve safety and effectiveness for people with gastrointestinal cancer who are starting this type of chemo for the first time.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.